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Therapy with mesenchymal stem cells (MSCs) has showed to be promising due to its immunomodulatory function. Traumatic
brain injury (TBI) triggers immune response and release of inﬂammatory mediators, mainly cytokines, by glial cells creating a
hostile microenvironment for endogenous neural stem cells (NSCs). We investigated the eﬀects of factors secreted by MSCs on
NSC in vitro and analyzed cytokines expression in vitro in a TBI model. Our in vitro results show that MSC-secreted factors
increase NSC proliferation and induce higher expression of GFAP, indicating a tendency toward diﬀerentiation into astrocytes.
In vivo experiments showed that MSC injection at an acute model of brain injury diminishes a broad proﬁle of cytokines in the
tissue, suggesting that MSC-secreted factors may modulate the inﬂammation at the injury site, which may be of interest to the
development of a favorable microenvironment for endogenous NSC and consequently to repair the injured tissue.
1.Background
For many years, the central nervous system (CNS) was
considered an immunologically privileged site, due to its
particular and limited immune response, diﬀerent from
other systems [1]. It is now clear that CNS is connected
to the immune and endocrine systems and has a local
inﬂammatory response, which can contribute to the patho-
physiology of acute and chronic brain diseases [2, 3]. Acute
neurodegenerative conditions such as traumatic brain injury
(TBI) are characterized by severe neuronal loss [4]. TBI
breaks the impermeability of the blood brain barrier, which
allows the invasion of immune cells and activation of glial
cells, mainly microglia and astrocytes, key cells for the
immune response within CNS, triggering the secretion of
inﬂammatory mediators by those cells [5, 6].
Inﬂammatory molecules are important in healthy ner-
vous tissue and their expression is promptly upregulated
when an injury occurs [3]. Cytokinesare the main molecules
in neuroinﬂammatory response and are critical for its
regulation, exerting a variety of activities [7, 8]. Microglia
and astrocytes release several cytokines, such as IL-1α,I L - 1 β,
IL-6, TNF-α,a n dT G F - β, chemokines, and prostaglandins,
which increase the blood brain barrier permeability and
facilitate the invasion of peripheral immune cells, inducing
the secretion of toxic molecules [3, 7].
In the adult brain, chemoattractants, including the
chemokine CXCL12 produced at the injury site induce neu-
roblasts originated by neural stem cells (NSC) at neurogenic
niches, such as the subventricular zone (SVZ), to migrate
towards the injury in order to regenerate the nervous tissue
[9–11]. Although neuroblasts leave the neurogenic niche
arrive at the injury site, only a few survive due to the
injury inﬂammatory microenvironment that is thought to
be unfavorable to neuroblast survival and diﬀerentiation
into mature neurons [12]. The limited CNS capacity of
regeneration and the complex environment created by TBI,
starting at the acute phase, followed by a secondary phase
that continues for weeks after the primary insult [13]
lead researchers to try to ﬁnd potential therapies using
neuroprotective and anti-inﬂammatory drugs [14–18].2 Neurology Research International
Cell-based therapy using adult-derived mesenchymal
stem cells (MSC) have been tested in several disease models
[19–24]. It is well accepted that transplantation of MSC,
particularly those derived from bone marrow, promotes
tissue repair via secreted soluble factors that enhance tissue
regeneration, stimulate proliferation, migration, and dif-
ferentiation of endogenous stem-like progenitors found in
most tissues, as well as by decreasing inﬂammatory and
immune reactions and apoptosis [25, 26]. The ability of
such cells to modify tissue microenvironment through its
trophic inﬂuence may contribute more signiﬁcantly than
their capacity for transdiﬀerentiation in eﬀecting tissue
repair.
I no r d e rt ob e t t e ru n d e r s t a n dt h ep a r a c r i n ee ﬀects of
MSC transplanted into an experimental brain injury site on
local cytokineproductionwe have used a TBI model inmice,
transplanted bone marrow-derived MSC into the lesion, and
analyzed the production of cytokines. We also investigated
the eﬀects of soluble factors secreted by MSC on neural stem
cells survival, proliferation, and diﬀerentiation in vitro.O u r
results show a decrease in the production of inﬂammatory
cytokines 24 hours after MSC transplantation. We also show
that soluble factors secreted by MSC increase proliferation
and modulate gene expression of neural stem cells in vitro,
increasing the expression of GFAP, a marker of glial cells.
2.MaterialandMethods
2.1.Animals. Adult(6-week-oldforMSCandNSCisolation,
12-week-old for TBI model) C57BL/6 male mice were
used in this study. The animals were maintained under
standard conditions (light/dark cycle 12h/12h, constant
room temperature at 22 ± 2◦C, food, and water ad libitum).
All the experimental procedures were conducted according
to international regulation and were approved by the Com-
mittee for Ethics in Research of Universidade Federal de S˜ ao
Paulo (approval no. 1367/08).
2.2. Isolation, Expansion, and Characterization of MSC. After
euthanasia in CO2 chamber, bone marrow was obtained
from femur of adult mice. The femora were removed,
cleaned, and placed in DMEM low glucose (Dulbecco’s
Modiﬁed Eagle’s Medium, GibcoBRL, San Francisco, USA).
Inside the laminar ﬂow, the epiphyses were cut and bone
marrow was ﬂushed by DMEM into a culture dish using a
syringe. The volume obtained from each femur was treated
separately. Bone marrow was suspended and centrifuged for
5 minutes at 400×g. The supernatant was discarded and the
cell pellet derivedfromeach femurwassuspended in DMEM
low glucose containing 10% fetal bovine serum (FBS, Culti-
lab, Campinas, SP, Brazil), 1% glutamine (Sigma Chemical
Co., St. Louis, MO, USA), and 1% penicillin/streptomycin
(GibcoBRL)and culturedin six-well culture dishes (Corning
Incorporated, NY, USA)at a volumeof3.5mL/well. Cultures
were kept in a humidiﬁed 5% CO2 incubator at 37◦Cf o r7 2
hours, when nonadherent cells were removed by changing
the medium. Culture medium was changed every 3 days
until adherent cells (MSC)reached 70–80%conﬂuence,then
cells were washed with 0.03% PBS/EDTA, detached with
0.1% trypsin (Cultilab), and replated in a 1:2 split ratio.
Diﬀerentiation potential was checked by culturing the MSC
under favorable conditions for adipogenic and osteogenic
diﬀerentiation, as previously described [27]. To obtain the
MSC conditioned medium (MSC-CM), conﬂuent cultures
(passages 5–10) were kept in DMEM low glucose containing
0.5% FBS for 96 hours. After this period, conditioned
medium was centrifuged for 5 minutes at 400×g, the
supernatant was collected, immediately frozen and kept at
−80◦C until its use.
2.3. Isolation of Adult NSC and Neurosphere Formation.
Adult NSC were obtained from adult C57BL/6 male mice
SVZ. After euthanasia by cervical dislocation, brain was
removed, the SVZ dissected under a microscope, and the
cells maintained in DMEM high glucose (GibcoBRL). After
sedimentation, supernatant was discarded, and cells were
dissociated by incubation with 0.1% trypsin/EDTA during
5m i n u t e sa t3 7 ◦C. FBS was added to stop trypsin action,
cells were centrifuged for 5 minutes at 400×g, and super-
natant was removed. Isolated cells were then suspended in
DMEM/F12 7:3 (v/v) (GibcoBRL), supplemented with 2%
B27 (GibcoBRL), 20ng/mL EGF (Sigma), 20ng/mL FGF2
(R&D, Minneapolis, MN, USA), 1% penicillin/streptomycin
(GibcoBRL),and5μg/mLheparin(Sigma).Aftermechanical
dissociation, cells were plated on a polyHEMA (Sigma)
precoated 75cm2 ﬂask at a density of 2.4 × 107 cells/ﬂask
or on a 24-well plate at a density of 2 × 106 cells/well.
Neurosphere formation takes up to 14–21 days to occur, and
during thattimeculturemediumwaschanged every4-5days
bycentrifugation for5minutes at400×g.Halfvolumeofthe
medium was replaced by fresh medium. Neurospheres were
cultured with or without MSC-CM for 2 days to evaluate
NSC viability and for 4 days to evaluate NSC survival and
diﬀerentiation.
2.4. MTT Assay. The MTT (3-(4,5-dimethylthiazol-yl)2,5-
diphenyltetrazolium bromide, Sigma) assay was performed
to evaluate NSC viability cultured for 48 hours in MSC-CM.
At the end of this period, neurospheres were centrifuged for
5 minutes at 400×g, supernatant was discarded, and 270μL
ofculturemediumand 30μL ofMTT solution(5mg/L)were
added to each well and incubated for 3 hours at 37◦C. After
this period, MTT solution was aspirated and the formazan
reaction products were dissolved by the addition of 180μlo f
dimethyl sulfoxide (DMSO, MP Biomedicals, Solon, Ohio,
USA) to each well. The plate was shaken for 15 minutes,
the content was transferred to a 96-well plate, and the
optical density was read at 540nm on an ELISA plate reader
(Labsystems Multiskan MS, Helsinki, Finland).
2.5. Proliferation Assay. In vitro adult NSC proliferation
was measured by ﬂow cytometry (FACSCalibur System, BD
Biosciences, San Jose, CA,U S A ,u s i n gt h es o f t w a r eWindows
Multiple Document Interface Flow Cytometry Application,
WinMDI Version 2.9, The Scripps Research Institute, San
Diego, CA, USA), after BrdU incorporation. Adult NSCNeurology Research International 3
were cultured as neurospheres and maintained for 4 days
in MSC-CM or in control medium (DMEM/F12 7:3 v/v,
supplemented with 2% B27, 20ng/mL EGF, 20ng/mL FGF2,
1% penicillin/streptomycin, and 5μg/mL heparin) at 37◦C.
BrdU was added during the last 24 hours before analysis.
Neurospheres were dissociated with 0.1% trypsin for 5
minutes at 37◦C, ﬁxed by 1% paraformaldehyde (PFA) in
0.1M PBS, incubated in 2M HCl for 1 hour at 37◦C, washed
with 0.1M PBS, blocked, and permeabilized with 10% FBS
and 0.1% TritonX-100 in 0.1M PBS. Cells were incubated
with anti-BrdU (rat IgG 1:300, Accurate Chemical and
Scientiﬁc Corporation, Westbury, NY, USA) for 1 hour and
washed with 0.1M PBS. Cells were then incubated with
secondary antibody (Alexa Fluor488-conjugated goat anti-
rat IgG, 1:300, Molecular Probes, Carlsbad, CA, USA) for
40 minutes.
2.6. Injury to Mice Primary Motor Cortex and MSC Trans-
plantation. A d u l tC 5 7 B L / 6m a l em i c ew e r es u b m i t t e dt o
surgery under anesthesia with intraperitoneal administra-
tion of xilasine (32mg/kg)/ketamine chloridrate (66mg/kg)
(Dopalen, Vetbrands, S˜ ao Paulo, Brazil). Traumatic injury to
mice motor cortex was performed according to previously
described protocol [28, 29]. Brieﬂy, a metal needle was
chilled using isopentane on dry ice and was inserted 4 times,
during 30 seconds each, into the motor cortex (stereotaxic
coordinates from bregma: AP +0.198mm; ML +0.175mm;
DV −0.15mm [30]). MSC (1 × 105 cells in 3μL) were
injected at the injury site using a Hamilton syringe under
the same stereotaxic coordinates and the same anesthesia,
immediately after the injury. Control consisted of animals
without injury and animals that were submitted to the injury
but did not receive MSC (injury, no treatment). Brain tissue
was collected 24 hours (acute injury) or 30 days (chronic
injury) after MSC injection. Mice were anesthetized by i.p.
injection of sodium thiopental (Tiopentax, Crist´ alia, S˜ ao
Paulo, Brazil), brain was removed from skull, the motor
cortex was dissected and total RNA was extracted by Trizol
Reagent (Life Technologies, Carlsbad, CA, USA). Animal’s
blood was collected by cardiac puncture, centrifuged to
separate the serum, which was immediately frozen in dry ice
and kept at −80◦Cu n t i lu s e .
2.7. qPCR. Total RNA was isolated from dissected motor
cortex or neurospheres using Trizol Reagent (Life Tech-
nologies), and RNA concentration was determined using
NanoDropND-1000(ThermoFisherScientiﬁc,Wilmington,
MA, USA). Reverse transcriptase reactions were performed
with ImProm-II Reverse Transcription System (Promega,
Madison, WI, USA) using 2μgo ft o t a lR N A .
Brain tissue samples qPCR was performed using ABI
PRISM 7500 Sequence Detector, using Sequence Detection
Software 1.9 for analysis (Applied Biosystems, Foster City,
CA, USA), using TaqMan probes (Applied Biosystems)
for HPRT (Mm00446968 m1; endogenous control gene),
IL-4 (Mm00445259 m1), IL-6 (Mm00446190 m1), IL-10
(Mm00439614 m1), and TNFα (Mm00443258 m1) accord-
ing to the manufacturer’s recommendations. Values are
expressed relatively to control RNA obtained from motor
cortex from mice that were not submitted to surgery.
Neurosphere samples qPCR was performed using Bril-
liant II SYBR Green QPCR Master Mix (Stratagene, La
Jolla, CA, EUA) using Mx3000P QPCR System using
MxPro qPCR Software for analysis (Stratagene). Primers
sequences were GAPDH (endogenous control gene; sense
5 -AAGAAGGTGGTGAAGCAGGCATCT-3 ;a n t i s e n s e5  -
ACCCTGTTGCTGTAGCCGTATTCA-3 ), GFAP (sense
5 -CTCAGTACGAGGCAGTGGCC-3 ;a n t i s e n s e5  -CGG-
GAAGCAACGTCTGTGA-3 ), nestin (sense 5 -AGCAAC-
TGGCACACCTCAAG-3 ;a n t i s e n s e5  -GGTGTCTGCAAG-
CGAAAGTTC-3 ), GAP-43 (sense 5 -AAGGAGGAGCCT-
AAACAAGCCGAT-3 ;a n t i s e n s e5  -TAGGTTTGGCTT-
CGTCTACAGCGT-3 ), and SOX2 (sense 5 -ATCCCATCC-
AAATTAACGCA-3 ;a n t i s e n s e5  -GAAGCGCCTAACGTA-
CCACT-3 ). Values are expressed relatively to RNA from
neurospheres cultured in regular medium (control).
The quantiﬁcation of the target genes was normalized by
an endogenous control gene (HPRT for brain tissue samples
and GAPDH for neurosphere samples). The threshold cycle
(Ct) for the target gene and the Ct for the internal control
were determined for each sample, run in triplicates. The
relative expression of mRNA was calculated by 2−ΔΔCt
method [31].
2.8. Bio-Plex. In order to analyze alterations in cytokines
expression in mice serum after TBI, a Bio-Plex assay was
performed. Custom Bio-Rad (Bio-Rad laboratories, Her-
cules, CA, USA). Bio-Plex cytokine analysis kits were used
together with the Bio-Plex system array reader according
to the manufacturer’s directions. The following cytokines
were quantiﬁed: CCL2 (MCP-1), CCL3 (MIP-1α), CCL4
(MIP-1β), CCL5(RANTES),eotaxin(CCL11),CXCL1(KC),
CXCL2(MIP-2),CXCL5(LIX),CXCL9(MIG),CXCL10(IP-
1 0 ) ,G - C S F ,G M - C S F ,I N F - γ,I L - 1 β, IL-4, IL-5, IL-6, IL-10,
IL-13, IL-17, LIF, TNF-α,a n dV E G F .S a m p l e sw e r er u ni n
triplicate for each assay. The assay was read on the Bio-Plex
suspension array system, and the data were analyzed using
Bio-Plex Manager software version 4.0. Standard curves
ranged from 10,000 to3,2pg/mL.
2.9. Statistical Analysis. Data are expressed as mean ± SEM.
Diﬀerences between groups were evaluated by one-way
analysisofvariance(ANOVA)followedbyTukey’sposttestby
the use of GraphPad Prism software version 4.0 (GraphPad
Software, La Jolla, CA, USA). Statistical signiﬁcance was set
at P<. 05.
3.Results
3.1. MSC Transplantation Modulates Cytokines Expression
after Acute Brain Injury. Acute TBI results in upregulation
of anti- and proinﬂammatory cytokines expression 24 hours
after the injury (Figure 1(a)). Thirty days after injury,
the expression levels of IL-10 and IL-4 are undetected
whereas the expression ofTNF-α persists signiﬁcantly higher4 Neurology Research International
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Figure 1: Relative expression of IL-6, TNF-α, IL-10, and IL-4 in acute and chronic models of motor cortex injury. (a) 24 hours and (b) 30
days after injury and MSC injection, RNA was extracted from motor cortex of control, injury without treatment and MSC treated mice.
qPCR was performed to quantify the expression of inﬂammatorycytokines and relative expression was calculated in relation to HPRT. Data
areexpressed as meanof2−ΔΔCt ±SEM (controln = 3, injuryno treatment n = 6,MSCtreated n = 4).
∗P <. 05,
∗∗P <. 001,
∗∗∗P <. 0001.
than in undamaged tissue and IL-6 expression decreases
(Figure 1(b)).
Our results show that immunomodulation by MSC
transplantation in theTBI acutemodel is indicatedbydown-
regulation of IL-6, and IL-10 mRNA levels (Figure 1(a)).
Thirty days after injury and injection of MSC, we observed
increased expression of IL-6 (Figure 1(b)).
3.2. Transplanted MSC also Modulate Serum Levels of
Cytokines. TBI induces an inﬂammatory reaction by the
release of proinﬂammatory cytokines IL-1β, IL-6, and IL-
8 that can be detected in the serum of patients that
have suﬀered severe TBI [32, 33]. There is very limited
informationaboutserumlevelsofcytokinesinTBImodelwe
used, especially regarding the levels of the pro-inﬂammatory
interleukins seen in patients. Similar to what is observed
for humans, the serum level of four pro-inﬂammatory
cytokines, IL-1β, IL-6, IL-17, and TNF-α was increased
by the injury (Figure 2(a)). We also observed increased
levels of two anti-inﬂammatory cytokines, IL-4 and IL-10
(Figure 2(b)). Interestingly, MSC transplantation into the
injury site decreased the serum levels of all cytokines in the
acute phase of the model (Figure 2).
We expanded the investigation of the levels of cytokines
to several chemokines, because of their important role in
the modulation of the activity of immune cells, as well as
of stem cells, especially regarding mobilization of stem cells
from tissue-speciﬁc stem cell niches [34, 35]. We observed a
variety of responses to injury and to MSC transplantation
in the acute (24 hours) and chronic (30 days) phases.
CCL5, CXCL9, and CXCL10 serum levels did not change in
response to injury or to MSC transplantation after injury,
in both acute and chronic phases (Figure 3). CCL2, CCL3,
CCL11, CXCL1, and G-CSF serum levels increased 24 hours
after injury in nontreated animals (Figure 3(a))whereas only
CCL2 and CCL11 returned to control levels after 30 days,
even without MSC transplantation (Figure 3(b)). GM-CSF
level was lower 24 hours after injury when compared to
s e r u ml e v e l sf r o mc o n t r o la n i m a l s( Figure 3(a)), and was
undetected after 30 days (Figure 3(b)).
MSC transplantation decreased serum levels of CCL2,
CCL11, CXCL1, CXCL5, CXCL9, CXCL2, and GM-CSF to
normal, or even below normal values, 24 hours after injury.
On theotherhand, analysisofserumofanimals thatreceived
MSCs 30 days after injury and transplantation showed that
the levels of CCL2, CCL11, and CXCL1 were higher than the
levels found in normal animals serum (Figure 3).
3.3. MSC-Conditioned Medium Stimulates Proliferation of
Neural Stem Cells and Modulates Gene Expression In Vitro.
Many reports describe that soluble factors secreted at brain
injury sites, including chemokines and cytokines, induce
neuralstemcellstomigratetowardstheinjurysite[36–38].A
recent study fromourlaboratory (unpublished data)showed
that peptides analogous to the chemokine CXCL12, known
to chemoattract cells that express the receptor CXCR4 such
as lymphocytes, progenitor cells, hematopoietic, neural, and
embryonic cells [39], stimulated chemotaxis of neuroblasts
towards a cortex injury site, and modulated gene expression
in vivo. Nevertheless, the hostile environment created by the
inﬂammatory mediators secreted by glial and immune cells
that inﬁltrate the injured brain reduces the survival of the
migrating neuroblasts.
The in vivo eﬀects of MSC immunomodulation that
we observed in the TBI model lead us to ask whether
MSC secrete factors that could modulate neural stem cells
survival, proliferation, and diﬀerentiation.I nvi t r otreatment
of neural stemcells derived from adult mice SVZ, culturedas
neurospheres, with MSC-conditioned medium (MSC-CM)
resulted in increased proliferation (Figure 4(a))w i t h o u t
aﬀecting survival of the cells (Figure 4(b)).Neurology Research International 5
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Figure 2: Cytokine proﬁle in serum in TBI acute phase. Serum from micesubmitted to the TBI protocol was used to investigate for cytokines
content. Mice were transplanted (MSC treated) or not (injury not treated) with MSC immediately after the injury and blood was collected
after 24hours.(a)Pro-inﬂammatorycytokines and(b) anti-inﬂammatorycytokines (controln = 3, injury no treatment n = 6,MSCtreated
n = 4).
∗∗∗P <. 001,
∗∗P <. 01.
Soluble factors present in MSC-CM changed neural
stem cell gene expression, inducing upregulation of GFAP, a
marker of astrocytes intermediate ﬁlaments, and downregu-
lation of nestin, a marker of immature cells (Figure 5). The
expression levels of GAP43, an axonal growth marker, and
SOX2, a neural stemness marker, did not change (Figure 5).
4.Discussion
Recently, the immunomodulatory properties of MSC have
been investigated in a number of pathological situations.
DespiteMSCmultipotencyandself-renewing characteristics,
studies suggest that the tissue regenerative potential exerted
bythesecellsare notduetotransdiﬀerentiationandsubstitu-
tionofdeadcells,butisduetothesecretionofsolublefactors
which stimulate local progenitor cells to survive, proliferate,
and diﬀerentiate [40, 41]. Several studies have demonstrated
this eﬀect in diﬀerent pathologies, such as acute kidney
injury [42], chronic renal failure [43], renal ﬁbrosis [44],
myocardium infarction [45], asthma [46], multiple sclerosis
and amyotrophic lateral sclerosis [47], and brain ischemia
[48]. In the present study, we used a murine TBI model
performed in the motor cortex of mice.
Our results show that 24 hours after the injury there
is a signiﬁcant increase in the expression of the pro-
inﬂammatory cytokines IL-6, and TNF-α in the injury
site (Figure 1). The increase in pro- and anti-inﬂammatory
mediators, such as IL-6, and IL-10, have been described in
cerebrospinal ﬂuid as well as in serum of patients with severe
TBI [49].
In the model we used, MSC transplantation signiﬁcantly
decreased the expression of IL-6, and similar results were
observed regarding the anti-inﬂammatory cytokines IL-10
and IL-4, both locally and in serum (Figures 1 and 2).
IL-6 is a pleiotropic cytokine, involved in several patho-
logical situations and can play pro- or anti-inﬂammatory
eﬀectsdependingonthemicroenvironment [50].Ourresults
show that there was an increase in IL-6 expression at the
injury site and also in serum (Figure 2). IL-6 is secreted
mainly by microglia and astrocytes, and its neuroprotector
role is characterized by TNF-α inhibition and NGF stimula-
tion. IL-6 also promotes tissue revascularization and tissue
scar formation [4]. Our results show increased IL-6 levels
30 days after injury and MSC transplantation, contrary to
i t sd e c r e a s ei nt h ea c u t ep h a s eo ft h ei n j u r y( 2 4h o u r s
after injury). These results suggest the immunomodulatory
property of MSC in the TBI model where in a hostile
environment in the acute period, when IL-6 is deleterious to
the tissue, MSC downregulates IL-6, while after a few days,
MSC upregulates IL-6, in a period when this chemokine
would become beneﬁcial to a possible tissue regeneration.
Besides the alterations in cytokines expressions in the site
of injury, MSC transplantation also inﬂuenced the levels
of chemokines systemically, both in the acute (24 hours)6 Neurology Research International
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Figure 3: Chemokine proﬁle in serum in TBI acute and chronic phase. Serum from mice submitted to the TBI protocol was used to
investigate for cytokines content. Mice were transplanted (MSC treated) or not (injury not treated) with MSC immediately after the injury
and blood was collected after 24 hours (acute phase) (a) or 30 days (chronic phase) (b). (control n = 3, injury no treatment n = 6, MSC
treated n = 4).
∗P <. 005,
∗∗∗P <. 001.
and chronic (30 days) phases of TBI (Figure 3). It has been
described that administration of IL-1β to the brain induces
hepaticCXCand CCLchemokine synthesis, which correlates
to elevation of circulating leukocytes in the blood [51].
CNS injury involves glial activation, leukocytes recruit-
ment, increase in the expression, and secretion of inﬂam-
matory mediators as cytokines, and chemokines [6]. Recent
studies have described molecular signals regulating NSC
migration in the injured brain, including angiogenic factors,
chemokines, cytokines and extracellular matrix components
[52]. Brain injury induces proliferation of NSC in the SVZ
and migration of neuroblasts from the SVZ towards the site
of the insult [53]. Nevertheless few neuroblasts arrive at the
injury site and survive to the injury microenvironment [12].
Our aim was to verify if the immunomodulatory prop-
erties observed in the in vivo experiments by the secretion
of soluble factors by MSC could have any direct eﬀect on
NSC survival, proliferation, and/or diﬀerentiation. In our
experiments, exposing NSC to soluble factors present in
MSC-CMdid not inﬂuence NSCapoptosis(data not shown)
and survival, but increased proliferation, indicating that the
factors secreted by MSC may contribute to enhancing the
number of NSC without aﬀecting survival (Figure 4).
On the other hand, MSC-CM soluble factors modu-
lated NSC gene expression, upregulating GFAP expression,
downregulation of nestin, and no alterations in GAP43
and SOX2 expression (Figure 5). SOX2 is a transcription
factor expressed by NSC present in neurogenic niches and
maintains pluripotency or stemness state [54]. Constitutive
expression of SOX2 inhibits neuronal diﬀerentiation, so this
could explain nestin downregulation.
5.Conclusion
In this study we observed that MSC are able to modulate
the inﬂammatory response in an acute TBI model by
changing the expression of pro- and anti-inﬂammatory
cytokines, along with modulation of serum levels of several
chemokines. In addition, MSC secreted soluble factors are
capableofstimulatingproliferationofNSCin vitro,asw ellas
increasing the expression of GFAP, a gene related to mature
astrocytes, indicating that factors expressed by MSC could
inducediﬀerentiationofNSCin vivo.Altogethertheseresults
indicate that there are still open possibilities of new regener-
ation therapies to treat nervous tissue injuries, highlightingNeurology Research International 7
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Figure 4: MSC secreted factors stimulate adult NSC proliferation. (a) Survival of NSC measured by MTT assay. (b) Proliferation of NSC
measured by BrdU incorporation using ﬂow cytometry. Data are mean ± SEM of two independent experiments performed in triplicates.
∗∗∗P <. 001.
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Figure 5: MSC secreted factors upregulate GFAP expression
by adult NSC. RNA was extracted from neurospheres cultured
in control medium or MSC-CM, and qPCR was performed to
evaluatethe expressionof GFAP, nestin,GAP43, andSOX2.Relative
expression was calculated in relation to GAPDH. Data expressed as
mean of 2−ΔΔCt ± SEM of triplicates.
∗P <. 05,
∗∗∗P <. 0001.
the importance of immunomodulatory properties of MSC
and its potential to allow NSC survival and proliferation.
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